Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.…
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
Kodiak Sciences (NASDAQ: KOD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 144 employees.
The shares were at 97.17 USD on 20 November 2026, up 451.2% over 52 weeks. Its 52-week range is 18.05 USD to 112.79 USD: the price is 13.8% below the high and 438.3% above the low.
Its market capitalisation is 6.35B USD.
Kodiak Sciences reports return on equity of -146.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 42.11M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 130.17 USD is 34.0% above the current price. The next earnings report is expected on 30 March 2027.